Moreover, preclinical studies support the therapeutic efficacy of AD-9308, angiotensin (1-7), and PI3Kγ inhibitors such as GE21 for diabetic cardiomyopathy, but evidence from clinical trials is lacking. The gene discussed is AGT; the disease is diabetic cardiomyopathy.